Wang Q, et al. - Researchers combined data from four cardiovascular outcomes trials and prospectively blinded endpoint adjudication to explore the long-term cardiovascular safety of GLP-1 RA (GLP-1 receptor agonist) use in diabetes patients with cardiovascular risk. The relationship between treatment and outcomes was assessed using the odds ratio and 95% confidence interval for cardiovascular outcomes. In diabetes patients with high cardiovascular risk or established cardiovascular disease, additional GLP-1 receptor agonists treatment did not increase cardiovascular outcomes.